MabSwitch utilizes a proprietary universal allosteric-linker and switch module for antibodies UNASMA technology to engineer control switches to regulate the activity and improve the efficacy of next-generation antibody-based immunotherapies. An awardee of a QuickFire Challenge sponsored by J&J and winner of two Biolabs Golden Tickets supported by Abbvie and BMS, Mabswitch recently was awarded a Phase 1 SBIR grant by the NIH to advance it's regulatable CAR-T cell therapy (SaefCAR) program.